Ignite Creation Date:
2025-12-26 @ 11:00 AM
Ignite Modification Date:
2026-01-01 @ 5:54 AM
Study NCT ID:
NCT05388006
Status:
RECRUITING
Last Update Posted:
2025-10-14
First Post:
2022-05-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Sponsor:
Mayo Clinic
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-01-05
Start Date Type:
ACTUAL
Primary Completion Date:
2027-02-22
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-02-22
Completion Date Type:
ESTIMATED
First Submit Date:
2022-05-19
First Submit QC Date:
None
Study First Post Date:
2022-05-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-09
Last Update Post Date:
2025-10-14
Last Update Post Date Type:
ESTIMATED